Studies on SLC2A6: A Protein Implicated in Many Physiological Processes

Target Name: SLC2A6

NCBI ID: G11182

SLC2A6

Studies on SLC2A6: A Protein Implicated in Many Physiological Processes

SLC2A6 (Sodium-Glucose cotransporter 2 subunit 6) is a protein that is expressed in most tissues of the body and plays a critical role in the transport of both sodium and glucose across cell membranes. It is a member of the SLC family of transport proteins, which are known for their ability to transport a wide variety of molecules across cell membranes. SLC2A6 is one of the most well-studied genes in the SLC family, and a number of studies have identified potential drug targets or biomarkers that can interact with this protein.

The SLC2A6 gene is located on chromosome 12q22 and has been studied extensively for its role in various physiological processes. One of the most well-known functions of SLC2A6 is its role in the regulation of intracellular glucose levels. SLC2A6 is expressed in most tissues of the body and is responsible for the reabsorption of glucose from the gut into the bloodstream. This is important for maintaining normal levels of glucose in the body, which is essential for maintaining energy metabolism and various physiological processes.

In addition to its role in glucose regulation, SLC2A6 has also been shown to play a number of other important roles in various physiological processes. For example, SLC2A6 has been shown to be involved in the regulation of ion channels, which are responsible for the flow of electrical currents through cell membranes. SLC2A6 has also been shown to be involved in the regulation of cell signaling pathways, which are responsible for transmitting signals from cells to other cells and for regulating various cellular processes.

SLC2A6 has also been shown to play a role in the development and progression of various diseases, including type 2 diabetes. Several studies have shown that SLC2A6 is expressed in the pancreatic beta cells, which are responsible for producing insulin to regulate blood glucose levels. In individuals with type 2 diabetes, the pancreatic beta cells are often damaged or destroyed, leading to a lack of insulin production and an increase in blood glucose levels. SLC2A6 has been shown to be involved in the regulation of insulin secretion from the pancreatic beta cells, and studies have suggested that targeting SLC2A6 may be a potential strategy for treating type 2 diabetes.

In addition to its potential as a drug target or biomarker, SLC2A6 has also been shown to be a potential biomarker for certain diseases. For example, SLC2A6 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and studies have suggested that targeting SLC2A6 may be a potential strategy for treating this disease. In addition, SLC2A6 has been shown to be expressed in the blood vessels of individuals with heart disease, and studies have suggested that targeting SLC2A6 may be a potential strategy for treating heart disease.

SLC2A6 has also been shown to play a role in the regulation of other physiological processes, including blood pressure and water balance. In addition, SLC2A6 has been shown to be involved in the regulation of the immune system, which is responsible for protecting the body against infection and disease.

In conclusion, SLC2A6 is a well-studied protein that plays a critical role in various physiological processes in the body. In addition to its role in glucose regulation, SLC2A6 has also been shown to play a number of other important roles in various physiological processes, including the regulation of ion channels, cell signaling pathways, and insulin secretion. SLC2A6 has also been shown to play a role in the development and progression of various diseases, including type 2 diabetes, Alzheimer's disease, and heart disease. Given its diverse functions and the potential for targeting SLC2A6 as a drug

Protein Name: Solute Carrier Family 2 Member 6

Functions: Probable sugar transporter that acts as a regulator of glycolysis in macrophages (Probable). Does not transport glucose (PubMed:30431159)

The "SLC2A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets